Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Model Organisms Center, Inc. (688265.SS)
Shanghai, CN
Shanghai Model Organisms Center, Inc. (SMOC) is a prominent Chinese enterprise dedicated to the research and development of genetically engineered animal models. The company offers a broad spectrum of specialized rodent models, encompassing disease-specific, humanized, immunodeficient, tool, and fluorescent reporter strains of both mice and rats. Furthermore, SMOC produces custom cellular products, including fluorescently labeled, primary, and humanized cell lines. Beyond its core product offerings, SMOC delivers a comprehensive suite of support services. These include personalized model generation, animal husbandry and breeding programs, in-depth phenotypic analysis, and critical drug screening and evaluation services for preclinical research. Established in 2000, SMOC maintains its primary operations and corporate headquarters in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.17% | -0.60% | -7.39% | -11.22% | -7.60% | +0.49% | +55.10% | +0.37% | -40.59% | -40.59% | -40.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+10.5% ★ Q1'26: +12.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+425.0% ★ Q1'26: +190.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+7.8% ★ Q1'26: -59.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+1.1% ★ Q1'26: -4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+0.6% ★ Q1'26: -2.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-7.1% ★ Q1'26: -21.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.63× ★ Q1'26: -3.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|
| Revenue |
275.27M
est: 273.33M (+0.7%)
|
302.97M
est: 318.00M (-4.7%)
|
366.55M
est: 413.00M (-11.2%)
|
381.24M
est: 549.00M (-30.6%)
|
421.26M
est: 734.00M (-42.6%)
|
| EBITDA |
82.93M
est: 59.46M (+39.5%)
|
8.98M
est: 69.17M (-87.0%)
|
-1.30M
est: 89.84M (-101.4%)
|
42.31M
est: 65.20M (-35.1%)
|
65.48M
est: 87.17M (-24.9%)
|
| EBIT |
70.59M
est: 23.19M (+204.3%)
|
-9.45M
est: 26.98M (-135.0%)
|
-24.74M
est: 35.04M (-170.6%)
|
6.65M
est: 27.01M (-75.4%)
|
4.43M
est: 36.11M (-87.7%)
|
| Net Income |
60.86M
est: 61.71M (-1.4%)
|
-5.40M
est: 51.15M (-110.6%)
|
-20.58M
est: 12.18M (-269.0%)
|
6.50M
est: 26.40M (-75.4%)
|
31.44M
est: 52.04M (-39.6%)
|
| SGA |
57.58M
est: 38.18M (+50.8%)
|
94.88M
est: 44.42M (+113.6%)
|
107.52M
est: 57.69M (+86.4%)
|
111.61M
est: 125.38M (-11.0%)
|
14.08M
est: 167.62M (-91.6%)
|
| EPS |
1.04
est: 0.76 (+36.8%)
|
-0.07
est: 0.63 (-111.1%)
|
-0.26
est: 0.15 (-273.3%)
|
0.08
est: 0.35 (-77.1%)
|
0.42
est: 0.69 (-39.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongxiao Feng | Deputy General Manager | — | male |
| Mingjun Wang | GM, Acting Chief Financial Officer, Accounting Supervisor & Director | — | male |
| Ruilin Sun | Deputy General Manager | — | male |
| Wen Liu | Secretary of the Board of Directors | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688265.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
